CS MEDICA A/S, a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD, announced on June 10, 2024, its plans to spin off stocks and list its subsidiary CANNORDIC A/S on the German Stock Market (Intention to Float).

Today, the company announces its evaluation of the possibility of distributing CANNORDIC shares to existing CS MEDICA shareholders ahead of the planned initial public offering (IPO) in 2024, approved at the Extraordinary General Meeting (EGM) on June 28, 2024.

With the IPO of its subsidiary CANNORDIC on the horizon, CS MEDICA is exploring pre-rights share allocations to enhance value and show appreciation to its current shareholders. This approach aims to bolster CS MEDICA's financial strength while acknowledging those who have supported the company's journey.

Lone Henriksen, CEO of CS MEDICA, commented on the initiative: "Our exploration of pre-IPO share distribution is not just about protecting our share and value our shareholders. We see this as an opportunity to lay a stronger foundation for CANNORDIC with a shareholder base before the public listing this year's fall, ensuring continuity and stability in our growth track."